Current treatment of locoregional recurrence of melanoma

Current Oncology Reports

Volumn 15, Issue 5, 2013, Pages 465-472

  Squires III, Malcolm Hart ^a   Delman, Keith A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Electrochemotherapy; Isolated limb infusion; Isolated limb perfusion; Locoregional; Melanoma; Recurrence

Indexed keywords

ALLOVECTIN; ALPHA INTERFERON; BCG VACCINE; BETA INTERFERON; BLEOMYCIN; CISPLATIN; DIPHENCYPRONE; FLUOROURACIL; IMIQUIMOD; INTERLEUKIN 2; MELPHALAN; PV 10; ROSE BENGAL; TALIMOGENE LAHERPAREPVEC; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VELIMOGENE ALIPLASMID;

ALOPECIA; ARTICLE; CANCER IMMUNOTHERAPY; ELECTROCHEMOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HYPERTHERMIC ISOLATED LIMB PERFUSION; ISOLATED LIMB PERFUSION; LOW LEVEL LASER THERAPY; LYMPH NODE DISSECTION; LYMPHEDEMA; MELANOMA; MELANOMA METASTASIS; OVERALL SURVIVAL; RECURRENT DISEASE; REGIONAL PERFUSION; TOPICAL TREATMENT; VERRUCA VULGARIS; WIDE EXCISION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; ELECTROPORATION; HUMANS; IMMUNOTHERAPY; LASER THERAPY; MELANOMA; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS;

EID: 84884590353     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0333-5     Document Type: Article

References (84)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Karakousis CP, Balch CM, Urist MM, et al. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol. 1996;3(5):446-52.
3. Day Jr CL, Harrist TJ, Gorstein F, et al. Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg. 1981;194(1):108-12.
4. Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008;15(5):1476-84.
5. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622-34.
6. Dong XD, Tyler D, Johnson JL, et al. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer. 2000;88(5):1063-71.
7. Karakousis CP, Choe KJ, Holyoke ED. Biologic behavior and treatment of intransit metastasis of melanoma. Surg Gynecol Obstet. 1980;150(1):29-32.
8. Singletary SE, Tucker SL, Boddie Jr AW. Multivariate analysis of prognostic factors in regional cutaneous metastases of extremity melanoma. Cancer. 1988;61(7):1437-40.
9. Stucky CC, Gray RJ, Dueck AC, et al. Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am J Surg. 2010;200(6):770-4. discussion 744-5.
10. Grotz TE, Mansfield AS, Kottschade LA, et al. In-transit melanoma: an individualized approach. Oncology (Williston Park). 2011;25(14):1340-8.
11. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-206.
12. Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12(8):587-96.
13. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12(6):449-58.
14. Zogakis TG, Essner R, Wang HJ, et al. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol. 2007;14(5):1604-11.
15. Carlson GW, Page AJ, Cohen C, et al. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg. 2008;248(3):378-86.
16. Jones EL, Jones TS, Pearlman NW, et al. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 2013;148(5):456-61.
17. McDonald K, Page AJ, Jordan SW, et al. Analysis of regional recurrence after negative sentinel lymph node biopsy for head and neck melanoma. Head Neck. 2013;35(5):667-71.
18. Baker JJ, Ollila DW, Deal AM, et al. Early recurrence in sentinel lymph node positive stage III melanoma patients. Am Surg. 2012;78(7):808-13.
19. Coit DG, Andtbacka R, Bichakjian CK, et al. Melanoma. J Natl Compr Cancer Netw. 2009;7(3):250-75.
20. Testori A, Intelisano A, Verrecchia F, et al. Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role? Dermatol Ther. 2012;25(5):443-51.
21. Levine SM, Shapiro RL. Surgical treatment of malignant melanoma: practical guidelines. Dermatol Clin. 2012;30(3):487-501.
22. Yao KA, Hsueh EC, Essner R, et al. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg. 2003;238(5):743-7.
23. Coventry BJ, Chatterton B, Whitehead F, et al. Sentinel lymph node dissection and lymphatic mapping for local subcutaneous recurrence in melanoma treatment: longer-term follow-up results. Ann Surg Oncol. 2004;11(3 Suppl):203S-7S.
24. Beasley GM, Tyler DS. Treatment of in-transit melanoma: an opportunity to discover critical knowledge. Oncology (Williston Park). 2011;25(14):1351-2. 5.
25. Love TP, Delman KA. Management of regional lymph node basins in melanoma. Ochsner J. 2010;10(2):99-107.
26. Davis PG, Serpell JW, Kelly JW, Paul E. Axillary lymph node dissection for malignant melanoma. ANZ J Surg. 2011;81(6):462-6.
27. Shada AL, Walters DM, Tierney SN, Slingluff Jr CL. Surgical resection for bulky or recurrent axillary metastatic melanoma. J Surg Oncol. 2012;105(1):21-5.
28. Badgwell B, Xing Y, Gershenwald JE, et al. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol. 2007;14(10):2867-75.
29. Sawh-Martinez R, Salameh B, Colebunders B, et al. Level I sparing radical neck dissections for cutaneous melanoma in the lymphoscintigram era. Ann Plast Surg. 2012;69(4):422-4.
30. Young SE, Martinez SR, Faries MB, et al. Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes? Cancer J. 2006;12(3):207-11.
31. Khan N, Khan MK, Almasan A, et al. The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys. 2011;80(3):645-54.
32. •• Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13(6):589-97. A randomized, controlled trial demonstrated adjuvant radiation therapy following completion lymphadenectomy decreased lymph node field relapse versus observation, although no associated improvement in disease-specific or overall survival was seen.
33. Agrawal S, Kane 3rd JM, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer. 2009;115(24):5836-44.
34. Guadagnolo BA, Zagars GK. Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanoma. Lancet Oncol. 2009;10(4):409-16.
35. Creech Jr O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148(4):616-32.
36. Testori A, Verhoef C, Kroon HM, et al. Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. J Surg Oncol. 2011;104(4):397-404.
37. Pace M, Gattai R, Mascitelli EM, Millanta L. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases. J Surg Oncol. 2011;104(7):718-23.
38. • Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2011;213(2):306-16. This study provides the long-term results of a large single institution experience with the regional therapies of hyperthermic isolated limb perfusion and isolated limb infusion.
39. Gimbel MI, Delman KA, Zager JS. Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control. 2008;15(3):225-32.
40. Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial Z0020. J Clin Oncol. 2006;24(25):4196-201.
41. Alexander Jr HR, Fraker DL, Bartlett DL, et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol. 2010;28(1):114-8.
42. Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15(8):2195-205.
43. Rossi CR, Pasquali S, Mocellin S, et al. Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases. Ann Surg Oncol. 2010;17(11):3000-7.
44. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14(3):238-47.
45. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15(11):3003-13.
46. Wong J, Chen YA, Fisher KJ, Zager JS. Isolated limb infusion in a series of over 100 infusions: a single-center experience. Ann Surg Oncol. 2013;20(4):1121-7.
47. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208(5):706-15. discussion 715-7.
48. Sharma K, Beasley G, Turley R, et al. Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma. Ann Surg Oncol. 2012;19(8):2563-71.
49. Chai CY, Deneve JL, Beasley GM, et al. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol. 2012;19(5):1637-43.
50. Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer. 2009;115(9):1932-40.
51. • Beasley GM, Parsons C, Broadwater G, et al. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. Ann Surg. 2012;256(2):350-6. On prospective evaluation, FDG-PET/CT was shown to have limited value for predicting response to regional limb therapy, although in nearly half of patients, post-therapy surveillance scans were able to detect subclinical distant disease or regional nodal disease outside the treatment field that was still amenable to resection.
52. Testori A, Faries MB, Thompson JF, et al. Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol. 2011;104(4):391-6.
53. Martiniuk F, Damian DL, Thompson JF, et al. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone. J Drugs Dermatol. 2010;9(11):1368-72.
54. Damian DL, Thompson JF. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. J Am Acad Dermatol. 2007;56(5):869-71.
55. Damian DL, Shannon KF, Saw RP, Thompson JF. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol. 2009;50(4):266-71.
56. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3(2):196-200.
57. Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol. 1999;191(1):10-9.
58. Berman B, Poochareon VN, Villa AM. Novel dermatologic uses of the immune response modifier imiquimod 5% cream. Skin Ther Lett. 2002;7(9):1-6.
59. Florin V, Desmedt E, Vercambre-Darras S, Mortier L. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Investig New Drugs. 2012;30(4):1641-5.
60. Morton D, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970;68(1):158-63. discussion 163-4.
61. Kidner TB, Morton DL, Lee DJ, et al. Combined intralesional bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother. 2012;35(9):716-20.
62. Boyd KU, Wehrli BM, Temple CL. Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol. 2011;104(7):711-7.
63. Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer. 2003;89(9):1620-6.
64. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol. 2007;156(2):337-45.
65. Ridolfi L, Ridolfi R. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogastroenterology. 2002;49(44):335-9.
66. Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718-30.
67. Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010;6(6):941-9.
68. Andtbacka R, Collichio F, Amatruda T, et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol. 2013;31:suppl; abstr LBA9008.
69. von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer. 1988;61(6):1071-4.
70. Fujimura T, Okuyama R, Ohtani T, et al. Perilesional treatment of metastatic melanoma with interferon-beta. Clin Exp Dermatol. 2009;34(7):793-9.
71. Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional rose Bengal. Melanoma Res. 2008;18(6):405-11.
72. Bedikian AY, Richards J, Kharkevitch D, et al. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res. 2010;20(3):218-26.
73. Chowdhery R, Gonzalez R. Immunologic therapy targeting metastatic melanoma: allovectin-7. Immunotherapy. 2011;3(1):17-21.
74. Doukas J, Rolland A. Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. Cancer Gene Ther. 2012;19(12):811-7.
75. Kottschade LA, Weenig RH, Otley CC, et al. The use of pulsed dye laser in the treatment of melanoma metastatic to the skin: a Mayo Clinic case series. J Am Acad Dermatol. 2010;62(6):e22-5.
76. Gibson SC, Byrne DS, McKay AJ. Ten-year experience of carbon dioxide laser ablation as treatment for cutaneous recurrence of malignant melanoma. Br J Surg. 2004;91(7):893-5.
77. Olivier KR, Schild SE, Morris CG, et al. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer. 2007;110(8):1791-5.
78. Barker CA, Lee NY. Radiation therapy for cutaneous melanoma. Dermatol Clin. 2012;30(3):525-33.
79. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys. 1999;44(3):607-18.
80. Stevens G, Thompson JF, Firth I, et al. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer. 2000;88(1):88-94.
81. Stevens G, McKay MJ. Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncol. 2006;7(7):575-83.
82. Rao NG, Yu HH, Trotti 3rd A, Sondak VK. The role of radiation therapy in the management of cutaneous melanoma. Surg Oncol Clin N Am. 2011;20(1):115-31.
83. Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys. 1991;20(3):429-32.
84. Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys. 2006;66(4):1051-5.